LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Uždarymo kaina

10.27 3.74

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

9.9

Max

10.57

Pagrindiniai rodikliai
By Trading Economics
Pajamos	2.1M -17M
Darbuotojai	55
EBITDA	4.7M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+75.95% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-09

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	210M 583M
Ankstesnė atidarymo kaina	6.53
Ankstesnė uždarymo kaina	10.27

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-03 18:43; UTC

Svarbiausios naujienos

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

2026-03-03 17:33; UTC

Įsigijimai, susijungimai, perėmimai

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

2026-03-03 23:45; UTC

Rinkos pokalbiai

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

2026-03-03 23:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

2026-03-03 23:25; UTC

Rinkos pokalbiai

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

2026-03-03 23:25; UTC

Rinkos pokalbiai

Global Energy Roundup: Market Talk

2026-03-03 22:38; UTC

Svarbiausios naujienos

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

2026-03-03 22:16; UTC

Uždarbis

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

2026-03-03 22:09; UTC

Uždarbis

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

2026-03-03 22:06; UTC

Uždarbis

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

2026-03-03 22:05; UTC

Uždarbis

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

2026-03-03 22:03; UTC

Uždarbis

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

2026-03-03 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Tech, Media & Telecom Roundup: Market Talk

2026-03-03 21:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-03-03 21:45; UTC

Svarbiausios naujienos

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

2026-03-03 21:37; UTC

Uždarbis

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

2026-03-03 21:26; UTC

Svarbiausios naujienos

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

2026-03-03 20:31; UTC

Rinkos pokalbiai

Svarbiausios naujienos

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

2026-03-03 20:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

2026-03-03 19:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold and Silver Drop as Energy Surges -- Market Talk

2026-03-03 18:43; UTC

Uždarbis

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

2026-03-03 18:29; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Global Energy Roundup: Market Talk

2026-03-03 18:29; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

2026-03-03 18:22; UTC

Svarbiausios naujienos

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

2026-03-03 18:22; UTC

Svarbiausios naujienos

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

2026-03-03 18:17; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

2026-03-03 18:14; UTC

Uždarbis

How Long Can Anthropic Play Defense? -- WSJ

2026-03-03 17:41; UTC

Svarbiausios naujienos

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

2026-03-03 17:36; UTC

Svarbiausios naujienos

Iran Conflict is Starting to Boost Gasoline Prices -- Update

2026-03-03 17:28; UTC

Įsigijimai, susijungimai, perėmimai

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

75.95% į viršų

12 mėnesių prognozė

Vidutinis 18 USD 75.95%

Aukščiausias 18 USD

Žemiausias 18 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

Pirkti

Laikyti

Parduoti

Remiantis 1 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.